MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

HQY

95.46

-0.74%↓

TLRY

1.45

-2.03%↓

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

HQY

95.46

-0.74%↓

TLRY

1.45

-2.03%↓

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

HQY

95.46

-0.74%↓

TLRY

1.45

-2.03%↓

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

HQY

95.46

-0.74%↓

TLRY

1.45

-2.03%↓

MDT

95.84

-0.02%↓

VEEV

289.4

-0.16%↓

145.98

+0.05%↑

HQY

95.46

-0.74%↓

TLRY

1.45

-2.03%↓

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

27.55 -7.74

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

26.81

Максимум

29.47

Ключови измерители
By Trading Economics
Приходи	7M -102M
Продажби	996K 8.5M
Марж на печалбата	-1,208.257
Служители	509
EBITDA	17M -97M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+37.82% upside

Дивиденти
By Dow Jones
Следващи печалби	4.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	646M 2.6B
Предишно отваряне	35.29
Предишно затваряне	27.55

Настроения в новините

By Acuity

72%

28%

337 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.225 / 20.17 Подкрепа & съпротива

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.10.2025 г., 23:55 ч. UTC

Горещи акции

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21.10.2025 г., 23:49 ч. UTC

Печалби

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21.10.2025 г., 21:40 ч. UTC

Печалби

Waste Connections 3Q Revenue Rises

21.10.2025 г., 21:14 ч. UTC

Печалби

Значими двигатели на пазара

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21.10.2025 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21.10.2025 г., 20:57 ч. UTC

Придобивния, сливания и поглъщания

DraftKings to Launch Prediction Markets Platform

21.10.2025 г., 20:38 ч. UTC

Печалби

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21.10.2025 г., 20:35 ч. UTC

Печалби

Capital One 3Q Sales, Profit Jump

21.10.2025 г., 20:32 ч. UTC

Печалби

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21.10.2025 г., 23:44 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

21.10.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21.10.2025 г., 23:39 ч. UTC

Пазарно говорене

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21.10.2025 г., 23:36 ч. UTC

Пазарно говорене

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21.10.2025 г., 22:55 ч. UTC

Придобивния, сливания и поглъщания

Scentre Says This Forms Part of Capital Management Strategy

21.10.2025 г., 22:55 ч. UTC

Придобивния, сливания и поглъщания

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21.10.2025 г., 22:54 ч. UTC

Придобивния, сливания и поглъщания

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21.10.2025 г., 21:09 ч. UTC

Пазарно говорене

Печалби

Netflix Creators Have Started Using AI in Production -- Market Talk

21.10.2025 г., 20:58 ч. UTC

Пазарно говорене

Печалби

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

21.10.2025 г., 20:43 ч. UTC

Печалби

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21.10.2025 г., 20:41 ч. UTC

Печалби

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21.10.2025 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21.10.2025 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21.10.2025 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21.10.2025 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21.10.2025 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21.10.2025 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21.10.2025 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21.10.2025 г., 20:29 ч. UTC

Печалби

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

37.82% нагоре

12-месечна прогноза

Среден 42.2 USD 37.82%

Висок 80 USD

Нисък 20 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

337 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.